- Programs & Services
- Cost Management
- Specialty Management
- Care Management
- Member Engagement
- Health Plan Client Engagement
Aims to Help Improve Outcomes for Patients with Chronic Kidney Disease
At CVS Health, we are working to fundamentally transform the treatment paradigm for the millions of patients with chronic kidney disease (CKD) and end stage renal disease (ESRD) through CVS Kidney Care, a CVS Health company. We are focused on early identification of kidney disease, targeted patient engagement and ongoing education to help slow disease progression, and increasing access to transplants and home dialysis to optimize care for patients.
CVS Health is focused on optimizing care for patients with chronic kidney disease.
As part of our commitment to make home dialysis a real option for more patients, CVS Health has initiated a clinical trial designed to evaluate the safety and efficacy of the HemoCare Hemodialysis System. This innovative device includes unique safety features and is designed to make home hemodialysis simpler for patients. The trial, if successful, is a necessary step to receive market clearance of the HemoCare system by the U.S. Food and Drug Administration.
An estimated 37 million Americans live with CKD and nearly 700,000 have ESRD. Treatment can be challenging and costly for both patients and payors. In fact, dialysis alone costs Medicare approximately $35 billion annually. Despite the enormous cost, patient outcomes are poor, with nearly one in six dialysis patients dying in the first year of treatment.
Improved Access to Better Treatment Outcomes
Currently, hemodialysis, which uses a machine to mimic the role of a functioning kidney to clean a patient’s blood, is most commonly administered in a dialysis center three times per week for four hours a day. However, an expanding body of scientific literature indicates that clinical outcomes for hemodialysis patients can be improved if treatments are more frequent and longer in duration, which can be challenging to achieve through in-center dialysis.
CVS Kidney Care will also support other treatment options such as transplant and peritoneal dialysis.
Earlier Identification and Better Patient Education
Many people who have kidney disease don’t know it. In fact, in the U.S., 43 percent of those with severely reduced kidney function are not aware that they have CKD. By promoting early diagnosis, we will work to help delay the onset of dialysis and avoid emergency hospitalization, which is one of the biggest drivers of cost in kidney care.
As we expand our CVS Kidney Care programs and services, we will offer all-inclusive education to diagnosed patients, including face-to-face, personalized support and therapy education, as well as other proven patient engagement strategies. This begins with helping patients better understand the treatment options available to them, as well as educating them on critical factors such as kidney health, diet, comorbidities, and prescription management.
Aligned with HHS Priorities
Recently, an executive order aimed at improving kidney care helped launch a new Advancing Kidney Health initiative of the U.S. Department of Health and Human Services. This marked an important step forward in kidney care as the administration pledged to double the number of kidney transplants performed in the U.S. and reduce end-stage kidney failure by 25 percent by 2030 through better education and care during early forms of the disease.
Furthermore, the administration wants 80 percent of newly diagnosed people with end-stage kidney failure to receive a transplant or move from clinic-based dialysis to less expensive and more effective in-home care by 2025.
|Our CVS Kidney Care focus aligns with the core objectives of this new initiative, and we are committed to transforming the health care system to better meet the needs of patients and reduce overall costs. Our unique approach to kidney care is one way that we are doing this as we work to help more people on their path to better health.|
Optimizing prescription therapy is key to improving outcomes for chronic conditions that drive a majority of health care spend.
Our success in helping people on the path to better health depends on how well we engage members and encourage them to take the right steps.
The home hemodialysis device under development has not received market clearance from the FDA. The device will be studied in a clinical trial conducted by CVS Health.
CVS Health uses and shares data as allowed by applicable law, and by our agreements and our information firewall.
Image source: Licensed from Getty Images, 2019.
©2019 CVS Health. All rights reserved.